United States

Idera Pharmaceuticals Inc (IDRA.OQ)

IDRA.OQ on NASDAQ Stock Exchange Capital Market

17 Jan 2017
Change (% chg)

-- (--)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for IDRA.OQ


Idera Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapeutics for oncology and rare diseases. The Company utilizes two drug discovery technology platforms to design and develop drug candidates, which include Toll-like receptor (TLR) targeting... (more)


Beta: 2.52
Market Cap(Mil.): $222.96
Shares Outstanding(Mil.): 147.65
Dividend: --
Yield (%): --


  IDRA.OQ Industry Sector
P/E (TTM): -- 45.90 30.76
EPS (TTM): -0.42 -- --
ROI: -71.11 -1.00 14.82
ROE: -71.85 -0.71 16.24

BRIEF-Idera Pharmaceuticals and Vivelix Pharmaceuticals, Ltd enter into license agreement

* Press release - Idera Pharmaceuticals and Vivelix Pharmaceuticals, Ltd. Enter into exclusive license agreement for the worldwide rights to IMO-9200

Nov 28 2016

BRIEF-Idera reports data from ongoing Phase 1 clinical trial of intratumoral IMO-2125

* Idera Pharmaceuticals reports translational data supporting the mechanism of action of intratumoral IMO-2125 from ongoing Phase 1 dose escalation in clinical trial in combination with ipilimumab in metastatic melanoma patients refractory to anti-pd-1 trea Source text for Eikon: Further company coverage:

Nov 11 2016

BRIEF-Idera Pharmaceuticals Q3 loss per share $0.10

* Idera Pharmaceuticals reports third quarter 2016 financial results

Oct 28 2016

BRIEF-Baker Bros. Advisors LP reports 7.2 pct stake in Idera Pharmaceuticals - SEC filing

* Baker Bros. Advisors LP reports 7.2 percent stake in Idera Pharmaceuticals Inc as of Oct. 7 - sec filing Source text (http://bit.ly/2dOyHXg) Further company coverage:

Oct 11 2016

BRIEF-Idera Pharma says announces proposed public offering of common stock

* Idera pharmaceuticals inc says intends to offer and sell up to $50,000,000 of shares of its common stock in an underwritten public offering

Oct 05 2016

BRIEF-Idera Pharmaceuticals announced new pre-clinical data on mechanism of action supporting selective targeting of single point mutations

* Based on specificity in targeting RNA data indicates that 3GA could be used to treat diseases that require allele-specificity

Sep 27 2016

BRIEF-Idera Pharmaceuticals reports data from phase 1 trial of Intra-tumoral IMO-2125

* Idera Pharmaceuticals reports promising data from ongoing phase 1 dose escalation in clinical trial of intra-tumoral IMO-2125 in combination with Ipilimumab in patients with PD-1 refractory metastatic melanoma

Sep 26 2016

BRIEF-Idera Pharmaceuticals Q2 loss per share $0.11

* Idera Pharmaceuticals reports second quarter 2016 financial results and provides corporate update

Aug 02 2016

Earnings vs. Estimates